Ukuyeka unyango kunokubangela ukuba i-MS enzima ibuyele kwezinye
I-Tysabri (natalizumab) isicatshulwa esichaphazela isifo esisetyenziselwa ukuphinda kubuyiselwe abantu abano- multiple sclerosis (MS) . Iphazamisa amandla omzimba we-immune ukuwela umqobo wegazi-wengqondo ohlukanisa ubuchopho kunye nentambo yomthambo kuwo wonke umzimba. Zizo iiseli ezingabangela umonakalo kwiimbilini njengoko ziwahlula ngokukhawuleza ukugqoka kwazo (ezibizwa ngokuba yi- myelin sheath ).
I-Tysabri ivunywe yi-US Food and Drug Administration (FDA) ukuze isebenzise kwi-MS monotherapy (ukuba ingahlanganiswa nezinye iindlela zokwelapha) kwaye ilawulwa nge-intravenously zonke iintsuku ezingama-28.
Izingozi ezinxulumene neTysabri Usetyenziso
Ngoxa i-Tysabri iboniswe ukunciphisa ukuphindaphinda kubantu abane-MS ngamaphesenti ama-68, ayikho ngaphandle kwayo. Ngo-2005, i-FDA ikhishwe isilumkiso sebhokisi esimnyama ukucebisa izigulane kunye noogqirha ukuba iTysabri yayingama-2 kubonke abasebenzisi abayi-1 000 bafumana ukusuleleka kobuchopho obunokufa obubizwa ngokuba yi- letifenceal leukoencephalopathy (PML) .
Enye into eyaziwayo encinci yinto eyaziwa njenge-rebound apho ukuyeka okanye ukuphazanyiswa kweziyobisi kubangele ukubuya kwe- MS kwakhona , kwakhona kwezinye iziganeko zibi kunokuba xa kuqalwa unyango.
Ukuqonda Iimpembelelo eziPhambili
Impembelelo yeTysabri yaqale yachongwa ngo-2007 xa abaphandi baseDatshi bahlola i- MRI imiba yabantu ababebethabathe iTysabri kodwa bafanele bayeke xa isicatshulwa sikhutshwe okwesikhashana kwiimarike ngenxa yexhala le-PML.
Ngethuba leli gaba leenyanga le-15 lonyango, izazinzulu ziye zafumanisa ukuba inani eliphakathi kwezilonda kwi-central nervous system liye landa ukusuka kumyinge we-3.43 ekuqaleni kokunyango ukuya kwi-10.32 emva kokuba unyango lubekwe.
Okumangalisayo kukuba, le mpawu yayingabonakali ngakumbi kubantu ababesetyenziswe ixesha elide.
Enyanisweni, kwakunjalo. Ngokutsho kophando, abo babesele befumana unyango oluninzi lweTysabri lunezilonda eziphindwe kabini kunezo ziye zonyango lonke ixesha lokufunda (malunga nama-36 e-infusions).
Uvavanyo olulinganayo ngo-2014 lwaluxhasa le mabango kwaye lwagqiba ukuba ukuphazamiseka kwonyango kwaxhunyelelwa kwenyuka ngokuphindwe kabini kwengozini yokubuyela kuphinda. Okungakumbi malunga noko kwakungenxa yokuba isahlulo sababantu saphinda sabuya kwakhona emva kokuyeka iTysabri kunokuba ngaphambi kokuba unyango luqaliswe.
Oko Okusixelelayo
Izazinzulu azikwazi ngokupheleleyo ukuba kutheni le nzekayo eyenzekayo. Okufanayo kuphawulwe kwezinye izidakamizwa ze-MS, kuquka iGilenya (fingolimod) , kwaye akukho nzulu ingqiqo malunga nokuba yintoni enokwenziwa ukukhusela.
Oko esikwaziyo kukuba: abantu abasengozini enkulu yilabo bathatha iinyanga ezimbalwa zeTysabri baze bayeke. Ukuba unyango lunokucetyiswa ngeTysabri, wena njengesigulane kufuneka uzinikele kunyango kwaye unamathele kuyo. Awukwazi ukuthatha iiholide ezinobungozi okanye uthathe isigqibo sokumisa ukuba kwaye xa uziva ungcono.
Unyango ekugqibeleni kufuneka uqondiswe ngutitshala oqeqeshiweyo onokukwazi ukugqiba kakuhle ukuba kwaye xa i-Tysabri ingasadingeki.
> Imithombo:
> Fox, R .; Cree, et al. Umsebenzi wesifo se-MS kwi-REESTORE: isifundo se-natalizumab seentsuku ezingama-24 esingenakwenzeka. Neurology 2014; 82 (17): 1491-8.
> Sorensen, P .; Koch-Henrikson, H .; Petersen, T. et al. "Ukuphindaphinda okanye ukuhlaziywa kwekliniki kwakhona kubuyeka emva kokuyeka unyango lwe-natalizumab kwizigulane ze-MS ezinamandla." J Neurol . 2014; 261 (6): 1170-7.
> Vellinga, M .; Castelijns, J .; Barkhof, F. et al. Ukwanda kwe-postwithdrawal okwenyukayo kwintsebenzo ye-T2 kwi-patient ye-natalizumab ephathwa nge-MS. " Neurology. 2008; 70 (13): 1150-1.